The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018 and three additional anti-CGRP monoclonal antibodies (MAbs) racing to market. Aimovig is in the pole position as the first migraine-specific preventive therapy, the first major new entrant, and the first MAb to enter this highly underserved but heavily generic market since the approval of Allergan’s Botox in 2010. This U.S.-based launch-tracking series—DRG’s first in migraine—assesses Aimovig’s uptake and performance through year 1. Similar series to track the launches of future MAb competitors are also planned.
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch in a survey of U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Markets covered: United States.
Primary research: Survey of 75 U.S. neurologists for each wave.
Key metrics included: